Bibliography
- Yanagisawa M, Kurihara H, Kimura S, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1998;332:411-5
- Xu D, Emoto N, Giaid A, et al. ECE-1: a membrane-bound metalloprotease that catalyzes the proteolytic activation of big endothelin-1. Cell 1994;78:473-85
- Azarani A, Boileau G, Crine P. Recombinant human endothelin-converting enzyme ECE-1b is located in an intracellular compartment when expressed in polarized Madin–Darby canine kidney cells. Biochem J 1998;333:439-48
- Muller L, Barrett A, Etienne E, et al. Heterodimerization of endothelin-converting-enzyme-1 isoforms regulates the subcellular distribution of this metalloprotease. J Biol Chem 2003;278:545-55
- Turner AJ, Barnes K, Schweizer A, et al. Isoforms of endothelin-converting enzyme: why and where? TIPS 1998;19:483-6
- Valdenaire O, Lepailleur-Enouf D, Egidy G, et al. A fourth isoform of endothelin-converting enzyme (ECE-1) is generated from an additional promoter: molecular cloning and characterization. Eur J Biochem 1999;264:341-9
- Berger Y, Dehmlow H, Blum-Kaelin D, et al. Endothelin-converting-enzyme-1 inhibition and growth of human glioblastoma cells. J Med Chem 2005;48:483-98
- Russell FD, Coppell AL, Davenport AP. In vitro enzymatic processing of radiolabelled big ET-1 in human kidney. Biochem Pharm 1998;55:697-701
- Hayasaki-Kajiwara Y, Naya N, Shimamura T, et al. Endothelin generating pathway through endothelin1-31 in human cultured bronchial smooth muscle cells. Br J Pharmacol 1999;127:1415-21
- Lazarini F, Strosberg AD, Couraud PO, et al. Coupling of ETB endothelin receptor to mitogen-activated protein kinase stimulation and DNA synthesis in primary cultures of rat astrocytes. J Neurochem 1996;66:459-65
- Leach K, Turner D, Zhang W, et al. Endothelin-1 stimulates c-fos mRNA expression in C6 glioma cells via MAP kinase pathway. Peptides 1999;20:907-14
- Sasaki Y, Hori S, Oda K, et al. Both ETA and ETB receptors are involved in mitogen-activated protein kinase activation and DNA synthesis of astrocytes: study using ETB receptor-deficient rats (aganglionosis rats). Eur J Neurosci 1998;10:2984-93
- Bremnes T, Paasche JD, Mehlum A, et al. Regulation of intracellular trafficking pathways of the endothelin receptors. J Biol Chem 2000;275:17596-604
- Ishikawa K, Ihara M, Noguchi K, et al. Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ788. Proc Natl Acad Sci USA 1994;91:4892-6
- Jimeno A, Carducci M. Atrasentan: targeting the endothelin axis in prostate cancer. Expert Opin Invest Drugs 2004;13:1631-40
- Jimeno A, Carducci M. Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer. Expert Rev Anticancer Ther 2005;5:419-27
- Liu G. Recent advances in endothelin antagonism. Ann Rev Med Chem 2000;8:73-82
- Morris CD, Rose A, Curwen J, et al. Specific inhibition of the endothelin A receptor with ZD4054: clinical and pre-clinical evidence. Br J Cancer 2005;92:2148-52
- Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346:896-903
- Bourgeois C, Robert B, Rebourcet R, et al. Endothelin-1 and ETA receptor expression in vascular smooth muscle cells from human placenta: a new ETA receptor messenger ribonucleic acid is generated by alternative splicing of exon 3. J Clin Endocrinol Metab 1997;82:3116-23
- Elshourbagy NA, Adamou JE, Gagnon AW, et al. Molecular characterization of a novel human endothelin receptor splice variant. J Biol Chem 2000;271:25300-7
- Imamura F, Arimoto I, Fujiyoshi Y, et al. W276 mutation in the endothelin receptor subtype B impairs Gq coupling but not Gi or Go coupling. Biochem 2000;39:686-92
- Lo KW, Tsang YS, Kwong J, et al. Promoter hypermethylation of the EDNRB gene in nasopharyngeal carcinoma. Int J Cancer 2002;98:651-5
- Miyamoto Y, Yoshimasa T, Arai H, et al. Alternative RNA splicing of the human endothelin-A receptor generates multiple transcripts. Biochem J 1996;313:795-801
- Nambi P, Wu HL, Ye D, et al. Characterization of a novel porcine endothelin B receptor splice variant. J Pharm Exp Ther 2000;292:247-53
- Pao MM, Tsutsumi M, Liang G, et al. The endothelin receptor B (EDNRB) promoter displays heterogeneous, site specific methylation patterns in normal and tumor cells. Hum Mol Gen 2001;10:903-10
- Shyamala V, Moulthrop TH, Stratton-Thomas J, et al. Two distinct human endothelin B receptors generated by alternative splicing form a single gene. Cell Mol Biol Res 1994;40:285-96
- Tsutsumi M, Liang G, Jones PA. Novel endothelin B receptor transcripts with the potential of generating a new receptor. Gene 1999;228:43-9
- Zhang YF, Jeffery S, Burchill SA, et al. Truncated human endothelin receptor A produced by alternative splicing and its expression in melanoma. Br J Cancer 1998;78:1141-6
- Wenzel RR, Noll G, Luscher TF. Endothelin receptor antagonists inhibit endothelin in human skin microcirculation. Hypertension 1994;(23):581-6
- Kiowski W, Lüscher TF, Linder L, et al. Endothelin-1-induced vasoconstriction in humans. Reversal by calcium channel blockade but not nitrovasodilators or endothelium-derived relaxing factor. Circulation 1991;83:469-75
- Cardillo C, Kilcoyne CM, Waclawiw M, et al. Role of endothelin in the increased vascular tone of patients with essential hypertension. Hypertension 1999;33:753-8
- Goddard J, Johnston NR, Hand MF, et al. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004;109:1186-93
- Cowburn PJ, Cleland JG, McDonagh TA, et al. Comparison of selective ETA and ETB receptor antagonists in patients with chronic heart failure. Eur J Heart Fail 2005;7:37-42
- Battistini B, Berthiaume N, Kelland NF, et al. Profile of past and current clinical trials involving endothelin receptor antagonists: the novel “-sentan” class of drug. Exp Biol Med 2006;231:653-95
- Naito S, Shimizu S, Maeda S, et al. Ets-1 is an early response gene activated by ET-1 and PDGF-BB in vascular smooth muscle cells. Am J Physiol 1998;274:C472-80
- Salani D, Taraboletti G, Rosano L, et al. Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am J Pathol 2000;157:1703-11
- Sutsch G, Kiowski W, Yan XW, et al. Short-term oral endothelin-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure. Circulation 1998;98:2262-68
- Giverz MM, Colucci WS, Lejemtel TH, et al. Acute endothelin A receptor blockade causes selective pulmonary vasodilatation in patients with chronic heart failure. Circulation 2000;101:2922-7
- Mylona P, Cleland JG. Update of REACH-1 and MERIT-HF clinical trials in heart failure. Cardio.net Editorial Team. Eur J Heart Failure 2000;1:197-200
- Teerlink JR. Recent heart failure trials of neurohormonal modulation (OVERTURE and ENABLE): approaching the asymptote of efficacy ? J Card Fail 2002;8:124-7
- Abrahams W. Progress in clinical trials: ENCOR. Clin Cardiol 2001;24:481-3
- Anand I, McMurray J, Cohn JN, et al. Long-term effects of darusentan on left ventricular remodeling and clinical outcomes in the endothelin A receptor antagonist trial in heart failure (EARTH): randomized, double-blind, placebo-controlled trial. Lancet 2004;364:347-54
- Kelland NF, Webb DJ. Clinical trials of endothelin antagonists in heart failure: a question of dose? Exp Biol Med 2006;231:696-9
- Sasser JM, Sullivan JC, Hobbs JL, et al. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007;18:143-54
- Dhaun N, Ferro CJ, Davenport AP, et al. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic renal disease. Nephrol Dial Transplant 2007;22:3228-34
- Wenzel RR, Littke T, Kuranoff S, et al. SPP301 (Avosentan) Endothelin Antagonist Evaluation in Diabetic Nephropathy Study Investigators. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009;20:655-64
- Smolander J, Vogt B, Maillard M, et al. Dose-dependent acute and sustained renal effects of the endothelin receptor antagonist avosentan in healthy subjects. Clin Pharmacol Ther 2009;85(6):628-34
- Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1 in the lungs of patients with pulmonary hypertension. N Engl J Med 1993;328:1732-9
- Eddahibi S, Raffestin B, Clozel M, et al. Protection from pulmonary hypertension with an orally active endothelin receptor antagonist in hypoxic rats. Am J Physiol 1995;268:H828-35
- Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomized placebo-controlled study. Lancet 2001;358:1119-23
- Hoeper MM, Halank M, Marx C, et al. Bosentan therapy for portopulmonary hypertension. Eur Respir J 2005;25:502-8
- Hoeper MM, Kramm T, Wilkens H, et al. Bosentan therapy for inoperable chronic thromboembolic pulmonary hypertension. Chest 2005;128:2363-7
- Hughes RJ, Jais X, Bonderman D, et al. The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J 2006;28:138-43
- Sitbon O, Beghetti M, Petit J, et al. Bosentan for the treatment of pulmonary arterial hypertension associated with congenital heart defects. Eur J Clin Invest 2006;36:25-31
- Stolz D, Rasch H, Linka A, et al. A randomized, controlled trial of bosentan in severe COPD. Eur Respir J 2008;32:619-28
- Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169:441-7
- Galie N, Badesch D, Oudiz R, et al. Ambrisentan therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2005;46:529-35
- Macchia A, Marchioli R, Marfisi R, et al. A meta-analysis of trials of pulmonary hypertension: a clinical condition looking for drugs and research methodology. Am Heart J 2007;153:1037-47
- Sauvageau S, Thorin E, Caron A, et al. Endothelin-1-induced pulmonary vasoreactivity is regulated by ETA and ETB receptor interactions. J Vasc Res 2007;44:375-81
- Porter KE, Olojugba DH, Masood I, et al. Endothelin-B receptors mediate intimal hyperplasia in an organ culture of human saphenous vein. J Vasc Surg 1998;28:695-701
- Galiè N, Manes A, Negro L, et al. A meta-analysis of randomized controlled trials in pulmonary arterial hypertension. Eur Heart J 2009;30:394-403
- Vajkoczy P, Meyer B, Weidauer S, et al. Clazosentan (AXV-034343), a selective endothelin A receptor antagonist, in the prevention of cerebral vasospasm following severe aneurismal subarachnoid hemorrhage: results of a randomized, double-blind, placebo-controlled, multicenter Phase IIa study. J Neurochir 2005;103:9-17
- Shaw MD, Vermeulen M, Murray GD, et al. Efficacy and safety of the endothelin receptor antagonist TAK-044 in treating subarchnoid hemorrhage. J Neurosurg 2000;93:992-7
- McDonald RL, Kassel NF, Mayer S, et al. Clazosentan to overcome neurological ischemia and infarction occurring after subarachnoid hemorrhage (CONSCIOUS-1). Randomized, double-blind, placebo-controlled phase 2 dose-finding trial. Stroke 2008;39:3015-21
- Nelson J, Bagnato A, Battistini B, et al. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6
- Egidy G, Juillerat-Jeanneret L, Jeannin JF, et al. Modulation of human colon tumor-stromal interactions by the endothelin system. Am J Pathol 2000;157:1863-74
- Egidy G, Peduto Eberl L, Valdenaire O, et al. The endothelin system in human glioblastoma. Lab Invest 2000;80:1681-9
- Peduto Eberl L, Valdenaire O, SaintGiorgio V, et al. Endothelin receptor blockade potentiates FasL-induced apoptosis in rat colon carcinoma cells. Int J Cancer 2000;86:182-7
- Peduto Eberl L, Bovey R, Juillerat-Jeanneret L. Endothelin-receptor antagonists are pro-apoptotic and anti-proliferative in human colon cancer cells. Br J Cancer 2003;88:788-95
- Patel KV, Schrey MP. Endothelins in breast cancer. Cancer Treat Res 1996;83:369-94
- Douglas ML, Richardson MM, Nicol DL. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma. Cancer 2004;100:2118-24
- Grant K, Loizidou M, Taylor I. Endothelin-1: a multifunctional molecule in cancer. Br J Cancer 2003;88:163-6
- Grimshaw MJ. Endothelins in breast tumour cell invasion. Cancer Lett 2005;222:129-38
- Kusuhara M, Yamaguchi K, Nagasaki N, et al. Production of endothelin in human cancer cell lines. Cancer Res 1990;50:3257-61
- Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Translat Med 2004;2:16-24
- Berger Y, Chapuis Bernasconi C, Juillerat-Jeanneret L. Targeting the endothelin axis in human melanoma: combination of endothelin receptor antagonism and alkylating agents. Exp Biol Med 2006;231:111-9
- Lahav R, Heffner G, Patterson PH. An endothelin receptor B antagonist inhibits growth and induces cell death in human melanoma cells in vitro and in vivo. Proc Nat Acad Sci USA 1999;96:11496-500
- Kefford R, McNeil Beith J, Van Hazel GA, et al. A Phase II study of Bosentan, a dual endothelin receptor antagonist, as monotherapy in patients with stage IV metastatic melanoma. Invest New Drugs 2007;25:247-52
- Nelson JB, Love W, Chin JL, et al. Phase 3, randomized, controlled trial of atrasentan in patients with nonmetaststic hormone-refractory prostate cancer. Cancer 2008;113:2478-87
- Chiappori AA, Haura E, Rodriguet FA, et al. Phase I/II of Atrasentan, an endothelin A receptor antagonist, in combination with Paclitaxel and Carboplatin as first-line therapy in advanced non-small cell lung cancer. Clin Cancer Res 2008;14:1464-9
- Lalich M, McNeel DG, Wilding G, et al. Endothelin receptor antagonists in cancer therapy. Cancer Invest 2007;25:785-94
- Armstrong AJ, Creel P, Turnbull J, et al. A Phase I-II study of docetaxel and Atrasentan in men with castration-resistant metastatic prostate cancer. Clin Cancer Res 2008;14:6270-6
- Wynn TA. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210
- Gauldie J, Bonniaud P, Sime P, et al. TGF-β, Smad3 and the process of progressive fibrosis. Biochem Soc Trans 2007;35:661-4
- Clozel M, Salloukh H. Role of endothelin in fibrosis and anti-fibrotic potential of bosentan. Ann Med 2005;37:2-12
- Poncet S, Meyer S, Richard C, et al. The expression and function of the endothelin system in contractile properties of vaginal myofibroblasts of women with utero-vaginal prolapse. Am J Obst Gynecol 2005;192:426-32
- Antoniu SA. Targeting the endothelin pathway in the idiopathic pulmonary fibrosis: the role of bosentan. Exp Opin Ther Targets 2008;12:1077-84
- King TE. Bosentan for idiopathic pulmonary fibrosis. Curr Opin Invest Drugs 2008;9:1171-9
- Wenzel RR, Zbinden S, Noll G, et al. Endothelin-1 induces vasodilation in human skin by nociceptor fibres and release nitric oxide. Br J Clin Pharmacol 1998;45:441-6
- Vacca F, Bagnato A, Catt KJ, et al. Transactivation of the epidermal growth factor receptor in endothelin-1-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res 2000;60:5310-7
- Michaelson MD, Kaufman DS, Oh WK, et al. Randomized Phase II study of atrasentan alone or in combination with zoledronic acid in men with metastatic prostate cancer. Cancer 2006;107:530-5
- Pirtskhalaishvili G, Nelson JB. Endothelium-derived factors as paracrine mediators of prostate cancer progression. Prostate 2000;44:77-87
- Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47:2049-56
- Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-9
- Nelson JB. Endothelin receptor antagonists. World Urol J 2005;23:19-27
- Carducci M, Padley RJ, Breu J, et al. The effect of endothelin A receptor blockade with Atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, placebo controlled, trial. J Clin Oncol 2003;21:679-89
- Carducci MA, Saad F, Abrahamsson PA, et al. A phase 3 randomized controlled trial on the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer 2007;110:1959-66
- James ND, Caty A, Borre M, et al. Safety and efficacy of the specific endothelin-A receptor antagonist ZD4054 in patients with hormone-resistant prostate cancer and bone metastases who were pain free or mildly symptomatic: a double-blind, placebo-controlled, randomized, phase 2 trial. Eur Urol 2009;55:1112-23
- Warren R, Liu G. ZD4054: a specific endothelin A receptor antagonist with promising activity in metastatic castration-resistant prostate cancer. Expert Opin Invest Drugs 2008;17:1237-45